IMMUNE CHECKPOINT INHIBITION AND AUTOIMMUNITY: RHEUMATOLOGICAL PROBLEMS
https://doi.org/10.14412/1995-4484-2018-5-9
Abstract
The paper deals with the mechanisms of a T-cell immune response, which depends on the balance between costimulatory and coinhibitory signals that have been called as immune checkpoints (ICP). The imbalance of T-cell activation within ICTs (CTLA4/CD28 and PD1/PD1L) is considered to be a fundamental mechanism not only of autoimmune disease, but also impaired antitumor immunity underlying the development of malignant tumors. The use of monoclonal antibodies against negative regulatory ICTs (CTLA4, PD1, and PD1L) is a major achievement in the treatment of malignant neoplasms in the early 21st century. However, since CTLA4 and PD1 control the activation of auto-reactive T cells, the inhibition of these ICTs is associated with the development of autoimmune disease that is defined as immune-mediated adverse even. The paper considers the clinical manifestations of IMAR, primarily rheumatic ones and discusses the prospects of pharmacotherapy from the standpoint of achievements of modern rheumatology.
About the Author
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia; Department of Rheumatology, Institute of Professional Education, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow (Sechenov University).
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522;
28, Trubetskaya St., Build. 2, Moscow 119991
References
1. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi: 10.1172/JCI78088
2. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227-42. doi: 10.1038/nri3405
3. Насонов ЕЛ. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научно-практическая ревматология. 2015;53(5):522-41 [Nasonov EL. Abatacept for rheumatoid arthritis: A novel formulation, new mechanisms, new possibilities. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):522-41 (In Russ.)]. doi: 10.14412/1995-4484-2015-522-541
4. Buchbinder EI, Desari A. CTLA-4 and PD-1 pathways. Similarities, differences, and implications of their inhibition. Amer J Clin Oncol. 2016;39(1):98-106. doi: 10.1097/COC.0000000000000239
5. Padrol DM. The blockade on immune checkpoints in cancer immunotherapy. Nat Rev Immunol. 2012;12:252-64. doi: 10.1038/nrc3239
6. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017 May 5;23(5):540-7. doi: 10.1038/nm.4321
7. Cousin S, Italiano A. Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res. 2016;22:4550-5. doi: 10.1158/1078-0432.CCR-15-2569
8. Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017;6:73-82. doi: 10.2147/ITT.S126227
9. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48. doi: 10.1016/j.ejca.2015.11.016
10. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of antiPD-1 therapy. Eur J Cancer. 2016;60:210-25. doi: 10.1016/j.ejca.2016.02.024
11. Kostine M, Rouxel L, Barnetche T, et al; FHU ACRONIM. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2017 Nov 16. doi: 10.1136/annrheumdis-2017212257
12. Cappelli LC, Shah AA, Bingham CO 3rd. Immune-Related Adverse Effects of Cancer Immunotherapy – Implications for Rheumatology. Rheum Dis Clin North Am. 2017;43(1):65-78. doi: 10.1016/j.rdc.2016.09.007
13. Cappelli LC, Gutierrez AK, Bingham CO, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017;69:1751-63. doi: 10.1002/acr.23177
14. Calabrese C, Kirchner E, Kontzias K, et al. Rheumatic immunerelated adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412. doi: 10.1136/rmdopen-2016-000412
15. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, et al. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheum. 2017;69:687-99. doi: 10.1002/art.40043
16. Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017;22:627-30. doi: 10.1634/theoncologist.2016-0390
17. Rutgers A, van den Brom RRH, Hospers GAP, et al. Systemic vasculitis developed after immune checkpoint inhibition. Arthritis Care Res (Hoboken). 2017 Dec 1. doi: 10.1002/acr.23481
18. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheum. 2014;66:768-9. doi: 10.1002/art.38282
19. De Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheum. 2016;68:556-7. doi: 10.1002/art.39406
20. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76:43-50. doi: 10.1136/annrheumdis-2016-209595
21. Chan MM, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38:37-9. doi: 10.1097/CJI.0000000000000060
22. Law-Ping-Man S, Martin A, Briens E, et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford). 2016;55:2087-9. doi: 10.1093/rheumatology/kew281
23. Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A. 2017;114: E970-9. doi: 10.1073/pnas.1616848114
24. Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4:36. doi: 10.1186/s40425-016-0139-8
25. Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747-50. doi: 10.1136/annrheumdis-2017-211216
26. Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31:e254-7. doi: 10.1111/jdv.14011
27. Garel B, Kramkimel N, Trouvin AP, et al. Pembrolizumabinduced polymyalgia rheumatica in two patients with metastatic melanoma. Joint Bone Spine. 2017;84:233-4. doi: 10.1016/j.jbspin.2016.01.007
28. Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018 Jan 13. pii: S1568-9972(18)30010-7. doi: 10.1016/j.autrev.2018.01.003
29. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346-53. doi: 10.1001/jamaoncol.2016.1051
30. Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017 July 12. doi: 10.1016/j.autrev.2017.07.022
31. Van der Vlist M, Kuball J, Radstake TR, Meyaard L. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593604. doi: 10.1038/nrrheum.2016.131
32. Ma W-T, Chang C, Gershwin ME, Lian Z-X. Development of autoantibodies preceded clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmun. 2017;83:95-112. doi: 10.1016/j.jaut.2017.07.003
33. Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061-4. doi: 10.1136/annrheumdis2017-211560
34. Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376:1989-91. doi: 10.1056/NEJMc1703047
35. Bertrand F, Montfort A, Marcheteau E, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8(1):2256. doi: 10.1038/s41467-017-02358-7
Review
For citations:
Nasonov E.L. IMMUNE CHECKPOINT INHIBITION AND AUTOIMMUNITY: RHEUMATOLOGICAL PROBLEMS. Rheumatology Science and Practice. 2018;56(1):5-9. (In Russ.) https://doi.org/10.14412/1995-4484-2018-5-9
Views:
1206
Email this article 